IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Dr. Lal PathLabs IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 638.00 Cr. The company is based in New Delhi and caters to Healthcare sector. Citigroup Global Markets India , Kotak Mahindra Capital Company are the merchant bankers of Dr. Lal PathLabs IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 12th September 2015.
Dr. Lal PathLabs IPO posted revenues of ₹ 789.40 Cr. and PAT of ₹ 66.60 Cr. in FY16 on annualised basis.
Revenue:
₹ 789.40 Cr.
EBITDA Margin:
21.64
% 
Net Worth: ₹ 383.70 Cr.
Market Capitalisation:
[●]
P/E:
48.00 times
P/BV: [●]
EV/EBITDA: -0.88 times
Financial results of Dr. Lal PathLabs IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Sep-15 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 548.60 | 449.10 | 331.30 | 252.10 | |
| Net Worth | 383.70 | 319.10 | 215.70 | 151.80 | |
| Total Debt | [●] | [●] | 0.01 | [●] | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
394.70
789.40 |
640.10 | 543.80 | 423.80 | |
EBITDA
EBITDA on annualised basis |
85.40
170.80 |
154.30 | 137.40 | 89.10 | |
PAT
PAT on annualised basis |
33.30
66.60 |
87.90 | 73.90 | 48.80 | |
Dr. Lal PathLabs IPO PAT Margin is 8.44 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Dr. Lal PathLabs IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Sep-15 | FY15 | FY14 | FY13 |
|---|---|---|---|---|
| EBITDA Margin (%) | 21.64 | 24.11 | 25.27 | 21.02 |
| PAT Margin (%) | 8.44 | 13.73 | 13.59 | 11.51 |
| EPS (₹) | 5.90 | 16.53 | 14.21 | 9.71 |
| ROE (%) | 8.68 | 27.55 | 34.26 | 32.15 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 6.07 | 19.57 | 22.31 | 19.36 |
| Debt to Equity | [●] | [●] | 0.00 | [●] |
The market Capitalisation of Dr. Lal PathLabs IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Dr. Lal PathLabs IPO prospectus highlights an Return on Equity (ROE) of 8.68 % , Return on Assets (ROA) of 6.07 %, and an EBITDA Margin of 21.64 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Dr. Lal PathLabs IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Dr. Lal PathLabs IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Dr. Lal PathLabs IPO has a Price-to-Earnings (PE) ratio of 48.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Dr. Lal PathLabs IPO reported revenue of ₹ 815.42 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Dr. Lal PathLabs IPO provide insights into sales growth, market demand, and business scalability.
Dr. Lal PathLabs recorded an EBITDA of ₹ 170.80 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Dr. Lal PathLabs Profit After Tax (PAT) is ₹ 66.60 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 789.40 Cr.
EBITDA Margin:
21.64
%
Net Worth: ₹ 383.70 Cr.
Market Capitalisation:
[●]
P/E:
48.00 times
P/BV: [●]
EV/EBITDA:
[●]
Dr. Lal PathLabs operates in Healthcare and Healthcare Tests And Services. The Issue is listed on BSE,NSE in Dec, 2015. Dr. Lal PathLabs IPO size was 638.00 with Issue price of 550.00 .
Merchant Banker(s) of Dr. Lal PathLabs IPO: Citigroup Global Markets India Private Limited , Kotak Mahindra Capital Company Limited
Dr. Lal PathLabs IPO subscription was 33.41 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Dr. Lal PathLabs IPO listed at a listing price of 824.15 against the offer price of 550.00.
The current market price of Dr. Lal PathLabs is 3003.50.
Why Us?
